Stocktoria
Scinai Immunotherapeutics Ltd. SCNI
Scinai Immunotherapeutics Ltd. (SCNI) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.3M at a -633.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.2 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SCNI | Scinai Immunotherapeutics Ltd. | 2/9 | — | — | — |
| PLUR | Pluri Inc. | 2/9 | — | — | — |
| OTLK | Outlook Therapeutics, Inc. | 1/9 | — | — | — |
| PROK | PROKIDNEY CORP. | 1/9 | — | — | — |
| IMA | ImageneBio, Inc. | 3/9 | 5.55 | — | — |
| CRDF | Cardiff Oncology, Inc. | 2/9 | — | — | — |
| HUMA | Humacyte, Inc. | 3/9 | — | — | — |
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
FAQ
Is SCNI financially healthy?
Scinai Immunotherapeutics Ltd.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does SCNI pay a dividend?
No, Scinai Immunotherapeutics Ltd. does not currently pay a dividend.
How profitable is SCNI?
In FY2025, Scinai Immunotherapeutics Ltd. had a net margin of -633.6% and a return on equity of -102.5%.
Is SCNI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Scinai Immunotherapeutics Ltd.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.